Oncolytics Biotech Inc. [NASDAQ: ONCY] surged by $0.53 during the normal trading session on Tuesday and reaching a high of $3.66 during the day while it closed the day at $3.60. The company report on March 11, 2021 that Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies, in poster presentations during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Details on the posters and corresponding abstracts are shown below. All posters will be made available on the conference website on April 10, 2021.
Oncolytics Biotech Inc. stock has also gained 15.38% of its value over the past 7 days. However, ONCY stock has inclined by 53.85% in the 3 months of the year. Over the past six months meanwhile, it has gained 95.12% and gained 51.26% year-on date.
The market cap for ONCY stock reached $184.72 million, with 44.14 million shares outstanding and 42.76 million shares in the current float. Compared to the average trading volume of 1.67M shares, ONCY reached a trading volume of 6790702 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Oncolytics Biotech Inc. [ONCY]:
H.C. Wainwright have made an estimate for Oncolytics Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 17, 2021.
The Average True Range (ATR) for Oncolytics Biotech Inc. is set at 0.35 The Price to Book ratio for the last quarter was 8.00, with the Price to Cash per share for the same quarter was set at 0.49.
ONCY stock trade performance evaluation
Oncolytics Biotech Inc. [ONCY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.38. With this latest performance, ONCY shares gained by 9.09% in over the last four-week period, additionally plugging by 95.12% over the last 6 months – not to mention a rise of 215.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONCY stock in for the last two-week period is set at 62.77, with the RSI for the last a single of trading hit 68.49, and the three-weeks RSI is set at 60.05 for Oncolytics Biotech Inc. [ONCY]. The present Moving Average for the last 50 days of trading for this stock 2.95, while it was recorded at 3.18 for the last single week of trading, and 2.32 for the last 200 days.
Oncolytics Biotech Inc. [ONCY]: An insightful look at the core fundamentals
Return on Total Capital for ONCY is now -199.26, given the latest momentum, and Return on Invested Capital for the company is -180.30. Return on Equity for this stock declined to -182.63, with Return on Assets sitting at -83.35. When it comes to the capital structure of this company, Oncolytics Biotech Inc. [ONCY] has a Total Debt to Total Equity ratio set at 1.62. Additionally, ONCY Total Debt to Total Capital is recorded at 1.60, with Total Debt to Total Assets ending up at 1.17. Long-Term Debt to Equity for the company is recorded at 0.62, with the Long-Term Debt to Total Capital now at 0.61.
Reflecting on the efficiency of the workforce at the company, Oncolytics Biotech Inc. [ONCY] managed to generate an average of -$900,202 per employee.Oncolytics Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.50 and a Current Ratio set at 12.50.
Oncolytics Biotech Inc. [ONCY]: Insider Ownership positions
There are presently around $4 million, or 2.50% of ONCY stock, in the hands of institutional investors. The top three institutional holders of ONCY stocks are: CREATIVE PLANNING with ownership of 180,000, which is approximately 5.882% of the company’s market cap and around 1.80% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 174,220 shares of the stock with an approximate value of $0.63 million in ONCY stocks shares; and TWO SIGMA ADVISERS, LP, currently with $0.45 million in ONCY stock with ownership of nearly 2.705% of the company’s market capitalization.
Positions in Oncolytics Biotech Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 16 institutional holders increased their position in Oncolytics Biotech Inc. [NASDAQ:ONCY] by around 437,556 shares. Additionally, 10 investors decreased positions by around 159,020 shares, while 15 investors held positions by with 475,553 shares. The mentioned changes placed institutional holdings at 1,072,129 shares, according to the latest SEC report filing. ONCY stock had 6 new institutional investments in for a total of 192,762 shares, while 6 institutional investors sold positions of 155,532 shares during the same period.